Navigation Links
Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
Date:5/11/2009

FRANKFORT, Mich., May 11 /PRNewswire/ -- The following is being released today by Howard E. Greene, Jr.

To my fellow shareholders:

As the founding CEO of Amylin and a board member for almost 22 years, I want you to know how I plan to vote at our annual meeting.

In my opinion Amylin's talented employee team has created one of the best product and technology platforms in the diabetes and obesity area. But, shareholders have suffered because sales results have not reflected the commercial potential of that platform.

I commend our present management team, under Dan Bradbury's leadership, for recognizing that they need to achieve a more effective working relationship with Lilly, and that they must design a more innovative strategy for convincing primary care physicians that Amylin's injectible medicines are their best treatment option for patients with diabetes.

Our board of directors will play a strategic role in meeting these challenges. I believe management will have more freedom to think outside of the box if we replace the directors most directly involved in crafting the disappointing commercialization strategy.

Also, with the departures of Ginger Graham and me, the Amylin board loses more than 60% of its stock ownership. I think our investors would be well served by adding directors who directly represent large shareholdings.

So, I have decided to vote for the slate proposed by Eastbourne, including the Icahn nominees.

Respectfully,

Howard E. Greene, Jr., Co-Founder of Amylin


'/>"/>
SOURCE Howard E. Greene, Jr.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... From industry leaders, sports stars, and Hollywood icons to thousands of everyday, ... had lost all hope. Their stories are told here. , Chapter 13: ... “Neil takes readers on a riveting journey through the past, present and future of ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading ... today the opening of an office in Taipei, Taiwan. This new location allows ... while developing new relationships in the region. Located in the Neihu area of ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this educational ... fume hood. Along with the advantages and disadvantages of ductless, filtered fume hoods, ... in the laboratory. , Attendees will learn from an industry expert about the ...
(Date:9/19/2017)... ... 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is ... "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 ... interest in the potential of stem cell therapy and a fast friendship was formed. , ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):